About this book:

Bristol-Myers Squibb, a global pharmaceutical powerhouse, boasts a rich history spanning nearly two centuries, originating from the distinct paths of Edward Squibb's meticulous pursuit of pharmaceutical purity and Bristol-Myers' entrepreneurial venture into consumer health. This comprehensive account traces the company's evolution from supplying medicines during the Civil War and pioneering the antibiotic era with penicillin, to its landmark 1989 merger that forged a formidable leader in oncology and other critical therapeutic areas. The book highlights BMS's pivotal role in transforming cancer treatment through immuno-oncology breakthroughs like Opdivo and Yervoy, as well as its significant contributions in hematology (e.g., Revlimid, Abecma) and immunology (e.g., Orencia).

The narrative also details BMS's strategic fiscal management, including major acquisitions like Celgene, which brought in a robust pipeline and diversified its portfolio, and Karuna Therapeutics, which bolstered its neuroscience presence with innovative antipsychotics. Facing the persistent challenge of patent expirations, the company strategically invests over $11 billion annually in R&D, focusing on a "Growth Portfolio" of new medicines and embracing cutting-edge modalities from small molecules to cell and gene therapies, alongside AI and machine learning. Beyond scientific and financial achievements, "Bristol-Myers Squibb: The Story of An American Company" illuminates its deep commitment to corporate social responsibility, global health equity, and environmental sustainability, ensuring widespread access to life-saving treatments and fostering diverse and inclusive communities worldwide.

This compelling story is ideal for anyone interested in the history of medicine, the dynamics of the pharmaceutical industry, corporate strategy, or the intersection of science and global impact. It offers an in-depth look at how innovation, adaptability, and a patient-centric mission have enabled Bristol-Myers Squibb to navigate complex challenges, become a household name, and continuously reshape the future of human health.

What You'll Find Inside:

• **Dual Heritage and Landmark Merger:** Explore the distinct origins of Squibb, focused on pharmaceutical purity and innovation, and Bristol-Myers, a consumer product pioneer, and how their 1989 merger created a global biopharmaceutical powerhouse.
• **Transformative Impact of Penicillin & Antibiotics:** Understand Bristol-Myers Squibb's crucial role in the mass production of penicillin during World War II, ushering in the antibiotic era and fundamentally changing the fight against infectious diseases.
• **Pioneering Immuno-Oncology:** Discover how BMS revolutionized cancer treatment with groundbreaking immunotherapies like Yervoy (ipilimumab) and Opdivo (nivolumab), which harness the body's immune system to fight cancer.
• **Strategic Acquisitions and Diverse Pipeline:** Learn about the company's aggressive strategy of mega-acquisitions, including Celgene and Karuna Therapeutics, to significantly expand its pipeline across oncology, hematology, immunology, and neuroscience with both small and large molecules, cell, and gene therapies.
• **Commitment to Global Health and CSR:** Examine Bristol-Myers Squibb's extensive corporate social responsibility initiatives, including efforts to enhance health equity and access to medicines in low-income countries, and its dedication to environmental sustainability and community impact.

Who's It For:

This book is ideal for readers interested in the history of the pharmaceutical industry, corporate mergers, and the evolution of drug discovery. It will appeal to business students, healthcare professionals, and anyone curious about how major pharmaceutical companies navigate scientific advancements, market dynamics, and global health challenges to bring life-saving medicines to patients.